" class="no-js "lang="en-US"> Julien Miara - Medtech Alert
Wednesday, May 31, 2023

Breaking News

Cumulus Neuroscience Completes Patient Enrollment for Pivotal CNS-101 Early-Stage Alzheimer’s Dementia Validation Trial Cartography Biosciences Expands Scientific Advisory Board with Leading Antibody and Bi-specific Experts Mission Bio Launches Tapestri v3 to Rapidly Accelerate Rare Cell Detection Applications for Translational Research and Precision Therapeutics Ostentus Therapeutics and City of Hope to Continue Studies of Novel OST Natural Products for Treatment of Leukemia and Other Cancers Cellular Origins launches Constellation, its Configurable Robotic Platform to Enable Scalable Manufacture of Advanced Therapies Historic Milestone: UK Patients Receive First CannEpil® Delivery through ‘I AM Billy Foundation’ and GMC Specialist Register CANbridge Announces Full Enrollment Reached in China Region of the Global LIVMARLI® (CAN108) EMBARK Phase 2 Study in Biliary Atresia Juha Punnonen, M.D., Ph.D. Joins Hinge Bio as Chief Development Officer SNIPR Biome Reports Positive Clinical Interim Results for Groundbreaking, First-in-Human, CRISPR-based Microbial Gene Therapy Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
Julien Miara

Julien Miara

About Julien Miara

Related Story

Appointments

 Onxeo Appoints Julien Miara as New Interim CEO | Pharmtech Focus

Onxeo Appoints Julien Miara as New Interim CEO

January 4 2022

Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North: ONXEO), (“Onxeo” or “the Company”), a […]